TY - JOUR
T1 - National trends in ambulatory asthma treatment, 1997-2009
AU - Higashi, Ashley
AU - Zhu, Shu
AU - Stafford, Randall S.
AU - Alexander, G. Caleb
N1 - Funding Information:
Support: Dr. Alexander is supported by the Agency for Healthcare Research and Quality (K08 HS15699-01A1; RO1 HS0189960) and the Robert Wood Johnson Physician Faculty Scholars Program. The funding sources had no role in the design and conduct of the study, analysis or interpretation of the data; and preparation of final approval of the manuscript prior to publication.
PY - 2011/12
Y1 - 2011/12
N2 - BACKGROUND: Despite reductions in morbidity and mortality and changes in guidelines, little is known regarding changes in asthma treatment patterns. OBJECTIVE: To examine national trends in the office-based treatment of asthma between 1997 and 2009. PARTICIPANTS AND DESIGN: We used the National Ambulatory Care Survey (NAMCS) and the National Disease and Therapeutic Index™ (NDTI), nationally representative audits of office-based physicians, to examine patients diagnosed with asthma less than 50 years of age. MEASUREMENTS: Visits where asthma was diagnosed and use of six therapeutic classes (short-acting β 2 agonists [SABA], long-acting β 2 -agonists [LABA], inhaled steroids, antileukotrienes, anticholinergics, and xanthines). RESULTS: Estimates from NAMCS indicated modest increases in the number of annual asthma visits from 9.9 million [M] in 1997 to 10.3M during 2008; estimates from the NDTI suggested more gradual continuous increases from 8.7M in 1997 to 12.6M during 2009. NAMCS estimates indicated declines in use of SABAs (from 80% of treatment visits in 1997 to 71% in 2008), increased inhaled steroid use (24% in 1997 to 33% in 2008), increased use of fixed dose LABA/steroid combinations (0% in 1997 to 19% in 2008), and increased leukotriene use (9% in 1997 to 24% in 2008). The ratio of controller to total asthma medication use increased from 0.5 (1997) to a peak of 0.7 (2004). In 2008, anticholinergics, xanthines, and LABA use without concomitant steroids accounted for fewer than 4% of all treatment visits. Estimates from NDTI corroborated these trends. CONCLUSIONS: Changes in office-based treatment, including increased inhaled steroid use and increased combined steroid/long-acting β 2-agonist use coincide with reductions in asthma morbidity and mortality that have been demonstrated over the same period. Xanthines, anticholinergics, and increasingly, LABA without concomitant steroid use, account for a very small fraction of all asthma treatments.
AB - BACKGROUND: Despite reductions in morbidity and mortality and changes in guidelines, little is known regarding changes in asthma treatment patterns. OBJECTIVE: To examine national trends in the office-based treatment of asthma between 1997 and 2009. PARTICIPANTS AND DESIGN: We used the National Ambulatory Care Survey (NAMCS) and the National Disease and Therapeutic Index™ (NDTI), nationally representative audits of office-based physicians, to examine patients diagnosed with asthma less than 50 years of age. MEASUREMENTS: Visits where asthma was diagnosed and use of six therapeutic classes (short-acting β 2 agonists [SABA], long-acting β 2 -agonists [LABA], inhaled steroids, antileukotrienes, anticholinergics, and xanthines). RESULTS: Estimates from NAMCS indicated modest increases in the number of annual asthma visits from 9.9 million [M] in 1997 to 10.3M during 2008; estimates from the NDTI suggested more gradual continuous increases from 8.7M in 1997 to 12.6M during 2009. NAMCS estimates indicated declines in use of SABAs (from 80% of treatment visits in 1997 to 71% in 2008), increased inhaled steroid use (24% in 1997 to 33% in 2008), increased use of fixed dose LABA/steroid combinations (0% in 1997 to 19% in 2008), and increased leukotriene use (9% in 1997 to 24% in 2008). The ratio of controller to total asthma medication use increased from 0.5 (1997) to a peak of 0.7 (2004). In 2008, anticholinergics, xanthines, and LABA use without concomitant steroids accounted for fewer than 4% of all treatment visits. Estimates from NDTI corroborated these trends. CONCLUSIONS: Changes in office-based treatment, including increased inhaled steroid use and increased combined steroid/long-acting β 2-agonist use coincide with reductions in asthma morbidity and mortality that have been demonstrated over the same period. Xanthines, anticholinergics, and increasingly, LABA without concomitant steroid use, account for a very small fraction of all asthma treatments.
KW - pharmacotherapy
KW - primary care
KW - respiratory disease
UR - http://www.scopus.com/inward/record.url?scp=83655163892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83655163892&partnerID=8YFLogxK
U2 - 10.1007/s11606-011-1796-4
DO - 10.1007/s11606-011-1796-4
M3 - Article
C2 - 21769507
AN - SCOPUS:83655163892
SN - 0884-8734
VL - 26
SP - 1465
EP - 1470
JO - Journal of general internal medicine
JF - Journal of general internal medicine
IS - 12
ER -